Octreotide Acetate Injection
Formulation (FDF) · Injection · (1)1 ml:0.05 mg (2)1ml:0.1mg (3)1ml:0.3mg
Formulation (FDF)Confidentiality：Public
- INN / Generic Name
- Octreotide Acetate Injection
- Dosage Form
- Injection
- Strength
- (1)1 ml:0.05 mg (2)1ml:0.1mg (3)1ml:0.3mg
- Therapy Area
- Metabolic & Endocrinology
- Indication
- Acromegaly; Gastroenteropancreatic neuroendocrine tumour; Prophylaxis of complications after pancreatic surgery; Gastrooesophageal variceal haemorrhage
- Current Status
- Official FDF licensing catalog (UB504)
- GMP Certification
- CN - NMPA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- Registered (market rights transferable / DCP·NP per market)
- MOQ
- On request
- Lead Time
- On request
- Price Range
- On request
HS Code
3002.15
Registrable Markets
China
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price